Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an educational grant from
Bristol Myers Squibb
Description:
Melanoma is the most serious type of skin cancer. It occurs in skins
cells called melanocytes, and while it is predominantly found in the
skin, it can occur in any area of the body that contains melanocytes.
Melanoma will be found in approximately 106,110 people in the United
States in 2022 according to the National Cancer Institute. While it
is the least common amongst skin cancers, it is by far the
deadliest, with 7,180 people expected to die in 2022. Both of those
numbers have been rising in recent years. In the early stages of
melanoma, prognosis is usually good for patients, but when the
melanoma becomes metastatic and spreads to other areas of the body,
prognosis is especially poor. Fortunately for patients with
metastatic melanoma, and the physicians that treat them, significant
progress has been made in the treatment of this deadly disease over
the past few years, especially in the area of immunotherapies and
novel combinations.
Upon completion of this
activity, participants will be able to:
-
Discuss the clinical and economic
burden of melanoma, including factors that contribute to poor
prognosis and increased costs
-
Explore recent clinical data and
updates regarding immunotherapy as single-agent or in
combination strategies in the treatment of metastatic melanoma
-
Analyze the role of lag-3 blocking
antibodies in combination with immune checkpoint inhibitors for
patients with metastatic melanoma
-
Identify patients with metastatic
melanoma who may benefit from combination immune checkpoint
inhibitor-based treatment
-
Examine adverse events that may
occur with the use of immune checkpoint inhibitor-based
combinations and how they should be identified and managed for
improved patient adherence and quality of life
-
Assess managed care considerations
to facilitate optimal use of novel combination options,
including ICI-based combinations, in metastatic melanoma
|
Faculty: |
Hussein A. Tawbi, MD,
PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center |
|
Disclosure:
|
(Relevant
Financial Relationships with Ineligible Companies in the
Last 24 Months):
Dr. Tawbi has served as a consultant for Bristol Myers
Squib, Boxer Capital, Eisai, Genentech, Iovance, Jazz
Pharmaceuticals, Karyopharm, Merck, Novartis, and
Pfizer. He has received grant/research support from
Bristol Myers Squib, Eisai, Genentech, GlaxoSmithKline,
Merck, Novartis, Pfizer, and RAPT. His presentation has
been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by
educational grant from
Bristol Myers Squibb
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |